BMO Capital Markets assumed coverage on shares of Astrazeneca PLC (NYSE:AZN) in a note issued to investors on Wednesday. The firm set an “outperform” rating on the stock.
AZN has been the topic of a number of other research reports. Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 9th. BidaskClub lowered shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Cowen and Company reiterated a “hold” rating and issued a $34.00 price objective on shares of Astrazeneca PLC in a research note on Friday, July 28th. Morgan Stanley lowered shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 28th. Finally, Barclays PLC reiterated an “overweight” rating on shares of Astrazeneca PLC in a research note on Thursday, July 13th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $32.97.
Shares of Astrazeneca PLC (NYSE:AZN) traded up 0.90% during midday trading on Wednesday, reaching $30.34. 9,305,002 shares of the company traded hands. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. The company has a market capitalization of $76.82 billion, a PE ratio of 19.90 and a beta of 0.74. The company has a 50 day moving average price of $30.39 and a 200 day moving average price of $31.61.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the prior year, the business posted $0.83 EPS. Astrazeneca PLC’s revenue for the quarter was down 9.9% compared to the same quarter last year. On average, analysts expect that Astrazeneca PLC will post $1.86 earnings per share for the current year.
WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/09/06/astrazeneca-plc-azn-coverage-initiated-by-analysts-at-bmo-capital-markets.html.
Institutional investors and hedge funds have recently bought and sold shares of the business. PVG Asset Management Corp purchased a new position in Astrazeneca PLC during the first quarter valued at $8,242,000. Liberty Mutual Group Asset Management Inc. purchased a new position in Astrazeneca PLC during the first quarter valued at $890,000. Oppenheimer Asset Management Inc. purchased a new position in Astrazeneca PLC during the first quarter valued at $12,038,000. Stifel Financial Corp lifted its holdings in Astrazeneca PLC by 53.2% during the first quarter. Stifel Financial Corp now owns 360,447 shares of the company’s stock valued at $11,242,000 after purchasing an additional 125,093 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its holdings in Astrazeneca PLC by 1.3% during the first quarter. Parkside Financial Bank & Trust now owns 7,040 shares of the company’s stock valued at $219,000 after purchasing an additional 90 shares in the last quarter. 14.18% of the stock is currently owned by institutional investors and hedge funds.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Astrazeneca PLC and related companies with MarketBeat.com’s FREE daily email newsletter.